Radotinib
货号：
19923-1mg 基本售价：
350.0 元 规格：
1 mg
产品信息
概述| 货号 | 19923-1mg |
| 描述 | Radotinib is a selective second generation tyrosine kinase inhibitor that targets both the wild-type and mutant forms of Bcr-Abl, with an IC50 value of 32.5 nM in Ba/F3 human chronic myeloid leukemia cells expressing the wild-type form.1 Radotinib also inhibits platelet-derived growth factor receptors (PDGFRs) α and β with IC50 values of 75.5 and 130 nM, respectively.2,3 Binding of radotinib to Bcr-Abl in vitro inhibits the phosphorylation of the downstream signaling mediator CrkL.3 In acute myeloid leukemia cells, in vitro treatment with radotinib at doses of 10-100 µM reduces viability, activates the mitochondrial apoptosis pathway, and promotes expression of the differentiation marker CD11b.2 |
| 别名 | IY-5511; |
性能| 供应商 | Cayman |
| 应用文献 |
1.Zabriskie, M.S.,Vellore, N.A.,Gantz, K.C., et al. Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. Leukemia 29(9), 1939-1942 (2015).
2.Heo, S.-K.,Noh, E.-K.,Yoon, D.-J., et al. Radotinib induces apoptosis of CD11b+ cells differentiated from acute myeloid leukemia cells. PLoS One 10(6), e0129853 (2015).
3.Kim, S.-H.,Menon, H.,Jootar, S., et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica 99(7), 1191-1196 (2014).
|
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 530.5 |
| 分子式 | C27H21F3N8O |
| CAS号 | 926037-48-1 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
